Previous 10 | Next 10 |
Pear’s second telehealth offering for reSET-O® is with QuickMD, a telemedicine platform providing consultations and urgent care Pear is working with QuickMD to assist eligible patients in their recovery from opioid use disorder Pear Therapeutics, In...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the 17th Annual Needham Technology & Media Conference on Wednesday, May ...
Our portfolio has eclipsed all benchmarks both on a YoY and YTD basis with our contrarian, obscure stock and mid-cap approach with an exaggerated risk aversion. We discuss the logic behind our general style and why it is structurally advantaged against indices, and how it contributed ...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Bank of America 2022 Healthcare Conference in Las Vegas on Tuesday, May ...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the company will issue its first quarter 2022 financial results after the close of market on Monday, Ma...
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the treatment of substance use and opioid use disorders Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializ...
The U.S. FDA has granted Safer Technologies Program (STeP) for Medical Devices designation to Pear Therapeutics' (NASDAQ:PEAR) Pear-010, a prescription digital therapeutic ("PDT") candidate for acute and chronic pain. The designation is granted to medical devices that can significantly improv...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs) , today announced it has received Safer Technologies Program (STeP) for Medical Devices designation from the U.S. Food an...
Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced management will participate in the following upcoming virtual investor conferences in April 2022. C...
Pear is working with select telehealth providers to put recovery in the hands of those seeking help remotely Pear’s first telehealth offering is with PursueCare, a leading telehealth addiction treatment provider, to offer patients an end-to-end virtual continuum o...